| Lee A Wilkinson, MD | |
|
112 N 7th St Dept Of, Chambersburg, PA 17201-1720 | |
| (717) 267-7973 | |
| (717) 267-7127 |
| Full Name | Lee A Wilkinson |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 14 Years |
| Location | 112 N 7th St Dept Of, Chambersburg, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487974994 | NPI | - | NPPES |
| 103020556 0001 | Medicaid | PA |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chambersburg Hospital | Chambersburg, PA | Hospital |
| Waynesboro Hospital | Waynesboro, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Chambersburg Pathology Associates, Inc | 0446296891 | 3 |
| The Chambersburg Hospital | 5496748303 | 27 |
| Waynesboro Hospital | 6305830936 | 28 |
News Archive
Allergan, Inc. ("Allergan" or the "Company") today acknowledged that Valeant Pharmaceuticals International, Inc. ("Valeant") and Pershing Square Capital Management, L.P. ("Pershing Square") have made a second revised, unsolicited proposal to acquire all of the outstanding shares of the Company for a combination of 0.83 of Valeant common shares, $72.00 in cash per share of common stock of the Company, and a Contingent Value Right (CVR) related to DARPin® sales (the "Re-Revised Proposal").
Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the emerging field of cancer metabolism, announced today that it has received funding from Accelerate Brain Cancer Cure (ABC2), a non-profit organization that supports brain cancer research. ABC2's funding will enable new research investigating IDH1 gene mutations in brain cancer, with the goal of supplementing Agios's ongoing research into the development of new IDH1 therapeutics and diagnostics.
Hizentra (IgPro20) provides primary immunodeficiency (PI) patients with a safe and effective alternative to other immunoglobulin therapies when given in equivalent doses, according to Phase III pivotal trial data presented today at the XIVth Meeting of the European Society for Immunodeficiencies (ESID).
Research released today in the American Journal of Public Health found evidence that the tobacco industry has manipulated menthol levels and created new cigarette brands with the intention of gaining market share among young adults and adolescents.
› Verified 3 days ago
| Entity Name | The Gettysburg Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366472706 PECOS PAC ID: 2769373331 Enrollment ID: O20040323000809 |
News Archive
Allergan, Inc. ("Allergan" or the "Company") today acknowledged that Valeant Pharmaceuticals International, Inc. ("Valeant") and Pershing Square Capital Management, L.P. ("Pershing Square") have made a second revised, unsolicited proposal to acquire all of the outstanding shares of the Company for a combination of 0.83 of Valeant common shares, $72.00 in cash per share of common stock of the Company, and a Contingent Value Right (CVR) related to DARPin® sales (the "Re-Revised Proposal").
Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the emerging field of cancer metabolism, announced today that it has received funding from Accelerate Brain Cancer Cure (ABC2), a non-profit organization that supports brain cancer research. ABC2's funding will enable new research investigating IDH1 gene mutations in brain cancer, with the goal of supplementing Agios's ongoing research into the development of new IDH1 therapeutics and diagnostics.
Hizentra (IgPro20) provides primary immunodeficiency (PI) patients with a safe and effective alternative to other immunoglobulin therapies when given in equivalent doses, according to Phase III pivotal trial data presented today at the XIVth Meeting of the European Society for Immunodeficiencies (ESID).
Research released today in the American Journal of Public Health found evidence that the tobacco industry has manipulated menthol levels and created new cigarette brands with the intention of gaining market share among young adults and adolescents.
› Verified 3 days ago
| Entity Name | Waynesboro Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740287093 PECOS PAC ID: 6305830936 Enrollment ID: O20040414001288 |
News Archive
Allergan, Inc. ("Allergan" or the "Company") today acknowledged that Valeant Pharmaceuticals International, Inc. ("Valeant") and Pershing Square Capital Management, L.P. ("Pershing Square") have made a second revised, unsolicited proposal to acquire all of the outstanding shares of the Company for a combination of 0.83 of Valeant common shares, $72.00 in cash per share of common stock of the Company, and a Contingent Value Right (CVR) related to DARPin® sales (the "Re-Revised Proposal").
Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the emerging field of cancer metabolism, announced today that it has received funding from Accelerate Brain Cancer Cure (ABC2), a non-profit organization that supports brain cancer research. ABC2's funding will enable new research investigating IDH1 gene mutations in brain cancer, with the goal of supplementing Agios's ongoing research into the development of new IDH1 therapeutics and diagnostics.
Hizentra (IgPro20) provides primary immunodeficiency (PI) patients with a safe and effective alternative to other immunoglobulin therapies when given in equivalent doses, according to Phase III pivotal trial data presented today at the XIVth Meeting of the European Society for Immunodeficiencies (ESID).
Research released today in the American Journal of Public Health found evidence that the tobacco industry has manipulated menthol levels and created new cigarette brands with the intention of gaining market share among young adults and adolescents.
› Verified 3 days ago
| Entity Name | Chambersburg Pathology Associates, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437111242 PECOS PAC ID: 0446296891 Enrollment ID: O20050707000339 |
News Archive
Allergan, Inc. ("Allergan" or the "Company") today acknowledged that Valeant Pharmaceuticals International, Inc. ("Valeant") and Pershing Square Capital Management, L.P. ("Pershing Square") have made a second revised, unsolicited proposal to acquire all of the outstanding shares of the Company for a combination of 0.83 of Valeant common shares, $72.00 in cash per share of common stock of the Company, and a Contingent Value Right (CVR) related to DARPin® sales (the "Re-Revised Proposal").
Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the emerging field of cancer metabolism, announced today that it has received funding from Accelerate Brain Cancer Cure (ABC2), a non-profit organization that supports brain cancer research. ABC2's funding will enable new research investigating IDH1 gene mutations in brain cancer, with the goal of supplementing Agios's ongoing research into the development of new IDH1 therapeutics and diagnostics.
Hizentra (IgPro20) provides primary immunodeficiency (PI) patients with a safe and effective alternative to other immunoglobulin therapies when given in equivalent doses, according to Phase III pivotal trial data presented today at the XIVth Meeting of the European Society for Immunodeficiencies (ESID).
Research released today in the American Journal of Public Health found evidence that the tobacco industry has manipulated menthol levels and created new cigarette brands with the intention of gaining market share among young adults and adolescents.
› Verified 3 days ago
| Entity Name | The Chambersburg Hospital |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1356669501 PECOS PAC ID: 5496748303 Enrollment ID: O20110808000626 |
News Archive
Allergan, Inc. ("Allergan" or the "Company") today acknowledged that Valeant Pharmaceuticals International, Inc. ("Valeant") and Pershing Square Capital Management, L.P. ("Pershing Square") have made a second revised, unsolicited proposal to acquire all of the outstanding shares of the Company for a combination of 0.83 of Valeant common shares, $72.00 in cash per share of common stock of the Company, and a Contingent Value Right (CVR) related to DARPin® sales (the "Re-Revised Proposal").
Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the emerging field of cancer metabolism, announced today that it has received funding from Accelerate Brain Cancer Cure (ABC2), a non-profit organization that supports brain cancer research. ABC2's funding will enable new research investigating IDH1 gene mutations in brain cancer, with the goal of supplementing Agios's ongoing research into the development of new IDH1 therapeutics and diagnostics.
Hizentra (IgPro20) provides primary immunodeficiency (PI) patients with a safe and effective alternative to other immunoglobulin therapies when given in equivalent doses, according to Phase III pivotal trial data presented today at the XIVth Meeting of the European Society for Immunodeficiencies (ESID).
Research released today in the American Journal of Public Health found evidence that the tobacco industry has manipulated menthol levels and created new cigarette brands with the intention of gaining market share among young adults and adolescents.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lee A Wilkinson, MD 112 N 7th St, Dept Of Pathology, Chambersburg, PA 17201-1720 Ph: (717) 267-7973 | Lee A Wilkinson, MD 112 N 7th St Dept Of, Chambersburg, PA 17201-1720 Ph: (717) 267-7973 |
News Archive
Allergan, Inc. ("Allergan" or the "Company") today acknowledged that Valeant Pharmaceuticals International, Inc. ("Valeant") and Pershing Square Capital Management, L.P. ("Pershing Square") have made a second revised, unsolicited proposal to acquire all of the outstanding shares of the Company for a combination of 0.83 of Valeant common shares, $72.00 in cash per share of common stock of the Company, and a Contingent Value Right (CVR) related to DARPin® sales (the "Re-Revised Proposal").
Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the emerging field of cancer metabolism, announced today that it has received funding from Accelerate Brain Cancer Cure (ABC2), a non-profit organization that supports brain cancer research. ABC2's funding will enable new research investigating IDH1 gene mutations in brain cancer, with the goal of supplementing Agios's ongoing research into the development of new IDH1 therapeutics and diagnostics.
Hizentra (IgPro20) provides primary immunodeficiency (PI) patients with a safe and effective alternative to other immunoglobulin therapies when given in equivalent doses, according to Phase III pivotal trial data presented today at the XIVth Meeting of the European Society for Immunodeficiencies (ESID).
Research released today in the American Journal of Public Health found evidence that the tobacco industry has manipulated menthol levels and created new cigarette brands with the intention of gaining market share among young adults and adolescents.
› Verified 3 days ago
Jennifer K. Henaghan, DO Pathology Medicare: Medicare Enrolled Practice Location: 112 N 7th St, Chambersburg, PA 17201 Phone: 717-267-7973 Fax: 717-267-7127 | |
Michael J. Rupp, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 112 N 7th St, Chambersburg, PA 17201 Phone: 717-267-7973 Fax: 717-267-7127 | |
Dr. Margaret M. Flanagan, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 112 N 7th St, Chambersburg, PA 17201 Phone: 814-643-6207 Fax: 814-643-6165 |